Saturday, September 23, 2017

MultiDop: multi - Doppler radar analysis suite





MultiDop: An open - source, Python - powered, multi - Doppler radar analysis suite

Abstract: Toward an Open-Source, Python-Powered, Multi-Doppler Radar Analysis Suite (97th American Meteorological Society Annual Meeting)

NASA Technical Reports Server (NTRS) - MultiDop: An Open-Source, Python-Powered, Multi-Doppler Radar Analysis Suite

Severe weather research often is facilitated by multi-Doppler radar syntheses to retrieve three-dimensional winds. While numerous techniques and software packages to perform these analyses have been developed over the years [e.g.,
to date none has been fully integrated within the Python software framework that has been growing in popularity within the weather radar science community.

This presentation discussed work that has been done to merge the three-dimensional variational analysis (3DVAR) approach developed at the University of Oklahoma with the Python Atmospheric Radiation Measurement Radar Toolkit (Py-ART) developed at Argonne National Laboratory. National Aeronautics and Space Administration (NASA) Marshall Space Flight Center (MSFC) has successfully produced a working Python-based prototype that is being released to the community at large.

The package, called MultiDop, is fully compatible with Py-ART but also takes advantage of the computational efficiency supplied by the original 3DVAR codebase. Example workflows will be described using Jupyter notebooks that ingest native spherical coordinate radar volumes, provide quality control, and then merge the data onto a common Cartesian grid and perform multiple-Doppler syntheses, with final products matching the Py-ART data model. Performance against other multi-Doppler packages (e.g., Custom Editing and Display of Reduced Information in Cartesian Space, or CEDRIC) [Reference Manual | Earth Observing Laboratory] will be assessed. The MultiDop package is intended for community use and community-directed future development via the NASA GitHub portal. MultiDop is a Python-based interface between the

C-based DDA code developed at University of Oklahoma [CIMMS: Corey Potvin] and

the Python Atmospheric Radiation Measurement Radar Toolkit (Py-ART) software developed at Argonne National Lab [pyart/advection.py at master · ARM-DOE/pyart · GitHub]. Use this software to perform 3D wind analyses using 2-3 independent Doppler radars.
Checkout of Multidop

MultiDop is available at GitHub - nasa/MultiDop: Multiple-Doppler Radar Analysis Toolkit (MultiDop)

https://github.com/nasa/MultiDop


Current version = 0.3, tested and working under Python 2.7 and 3.6 Also requires numpy, Py-ART, xarray, C compilers, and netCDF libraries
If you use MultiDop, you MUST cite the following papers:

Wednesday, September 6, 2017

2017 Annual Meeting- American Society for Radiation Oncology (ASTRO)

2017 Annual Meeting- American Society for Radiation Oncology (ASTRO)

September 24 – 27, 2017
San Diego Convention Center

The ASTRO Annual Meeting is the world's most important meeting for the radiation oncology community, with more than 11,000 people attending each year. Learn more about what to expect at the upcoming Annual Meeting in our Annual Meeting highlights video.

Program

  • Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer deaths worldwide are projected to continue to rise to more than 11 million in 2030. The American Cancer Society estimates that in 2017, 1.685 million new cases of cancer will be diagnosed. Nearly two-thirds of these patients will receive radiation therapy during their illness – most with the intent to cure the cancer. Advances in the applications, technologies and methodologies of radiation oncology continue to evolve rapidly and the delivery of radiation therapy has become more complex, making it imperative that the radiation oncology professional remain current in the state-of-the-art techniques. ASTRO is committed to providing educational programming that creates a forum for global collaboration on issues in radiation oncology to improve professional practice by increasing their level of knowledge, as required to improve competency and performance in the field of oncology.
  • Program Objectives

    At the conclusion of this activity, the learner will be able to:
    • Examine the advances in radiation oncology technology that help improve patient outcomes and quality of life.
    • Employ quality and safety measures in the delivery of radiation therapy. 
    • Demonstrate the value of radiation oncology to patients, referring physicians and the public.

 Sessions of Interest on Prostate Cancer:

Tuesday, September 5, 2017

SanDiego Informed Prostate Cancer Support Group Next Meeting



San Diego Informed Prostate Cancer Support Group Next Meeting

September 16 - ADVANCES IN RADIATION THERAPY

Brent Rose, MD
Assistant Professor Radiation Oncology University of California San Diego.
Brent Rose, MD, is a radiation oncologist who specializes in treating prostate cancer, head and neck cancer, skin cancer, brain metastases and primary brain tumors. As a radiation oncologist, Dr. Rose uses carefully targeted, high doses of radiation energy to destroy or damage cancer cells. His expertise includes conformal radiation therapy (CRT), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and high-dose rate (HDR) and low-dose rate (LDR) brachytherapy.
As an assistant professor in the Department of Radiation Medicine and Applied Sciences, Dr. Rose instructs medical students, residents and fellows at UC San Diego School of Medicine.
Dr. Rose is a dedicated clinical researcher who has published over 30 journal articles and textbook chapters. His interest include developing advanced imaging and treatment techniques to improve the efficacy and reduce the side effects of cancer treatments as well as studying health outcomes data to better understand the risk and benefits of treatment and enhance shared decision making with patients and their doctors. 
He is a member of several organizations, including the American Board of Radiology and the American Society for Therapeutic Radiology and Oncology.
A native of Southern California, Dr. Rose completed his undergraduate degree (B.S. in Biology) and Medical School (M.D.) at the University of California San Diego (UCSD). Following Medical School, he moved to Boston where he completed his internship in Internal Medicine at the Beth Israel Deaconess Medical Center and Radiation Oncology Residency at the Harvard Radiation Oncology Program.
After residency, Dr. Rose joined the UCSD Radiation Medicine and Applied Sciences faculty as an Assistant Professor where he specializes in advanced radiotherapy techniques for the treatment of genitourinary, central nervous system and head and neck cancers. 
Dr. Rose’s wife, Olga, is a pediatrician and they have a young son named Erik

Recent Publications:


GA-ASI Opens New Hangar for Grand Sky UAV Flight Test and Training Center

GA-ASI’S Flight Test and Training Center Opens New Hangar - UAS VISION

New Hangar Opens for GA-ASI's Flight Test and Training Center
Ribbon-Cutting Event Marks Completion of Permanent Hangar Facility in N.D.

GRAND FORKS – 22 August 2017 – General Atomics Aeronautical Systems, Inc. (GA-ASI) held a grand opening event yesterday for its new hangar at the Grand Sky Unmanned Aircraft System (UAS) Business Park near Grand Forks, North Dakota. The event included a ribbon-cutting ceremony to commemorate the completion of GA-ASI's new Flight Test and Training Center (FTTC) hangar.

The hangar replaces the temporary facility that has been in operation since June 2016. It will house GA-ASI operational hardware, including Remotely Piloted Aircraft (RPA) and Ground Control Stations (GCS), as well as offices and conference rooms.

"We're excited to open this new permanent hangar for our Flight Test and Training Center in North Dakota," said David R. Alexander, president, Aircraft Systems, GA-ASI. "It represents our investment in test and training capabilities, which will provide our customers with an excellent facility to train aircrews to fly our aircraft."

In addition to Mr. Alexander, Grand Opening festivities included remarks from U.S. Senator John Hoeven (R-ND); North Dakota Lieutenant Governor Brent Sanford; Field Representative Matthew Leiphon (U.S. Senator Heidi Heitkamp, D-ND); District Representative Randy Richards (U.S. Representative Kevin Cramer, R-ND); and GA-ASI Chief Executive Officer Linden Blue.

"As our UAS industry continues developing new applications for this technology in both the public and private sectors, it is vital that we have qualified operators for these aircraft," Hoeven said. "General Atomics' new training hangar is an international asset. UAS pilots from around the world will train right here in Grand Forks, further cementing our state's position as a leader in UAS research, training and operations."

The new hangar will house three GA-ASI owned RPA – a MQ-1 Predator® A and two MQ-9 Predator Bs/ (Block 1 and Block 5) – and two GCS (a Block 15 and Block 30 Mobile GCS). GA-ASI's FTTC operation also includes an office building located near the University of North Dakota campus that contains classrooms and a Predator Mission Aircrew Training System for accomplishing the academic and simulator segments of training.

"Grand Sky's goal is to create the operations-friendly environment tenants need to expand their capabilities as the UAS industry grows," said Thomas Swoyer Jr., president of Grand Sky Development Company. "From being the first to fly large UAS at the park to being the first to expand their operations, GA-ASI continues to operate at the leading edge of the industry. We're proud to count them as a partner for many years to come."

 

Related/Background:

x

Monday, September 4, 2017

#ProstateCancer News - 2017 -09 September

Prostate Cancer News - 2017-09

General News

About prostate cancer research, cases and public awareness:

Case Management

Planning a campaign against prostate cancer:

Life Choices

can influence the odds in your favor:

Diet

can starve the cancer

Exercise

can give you strength to fight the cancer and treatment side effects

Screening and Diagnosis

early detection is important because symptoms appear too late for treatment:

Biopsies and Pathology

Genomics

Tests

Imaging

Treatment

Active Surveillance AS

Surgery RP

frequently the first choice for localized PCa, robotic assist dominates:

Radiation RT

Hormone ADT

Chemo


Immunotherapy

New Techniques

Side Effects

Advanced/Recurrence


Friday, September 1, 2017

September is Prostate Cancer Awareness Month

Prostate cancer
The American Cancer Society recommends that men make an informed decision with their doctor about whether to be tested for prostate cancer. Research has not yet proven that the potential benefits of testing outweigh the harms of testing and treatment. The American Cancer Society believes that men should not be tested without learning about what we know and don’t know about the risks and possible benefits of testing and treatment.

Starting at age 50, men should talk to a doctor about the pros and cons of testing so they can decide if testing is the right choice for them. If they are African American or have a father or brother who had prostate cancer before age 65, men should have this talk with a doctor starting at age 45. If men decide to be tested, they should have the PSA blood test with or without a rectal exam. How often they are tested will depend on their PSA level.

http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer

Statement from President Donald J. Trump on National Prostate Cancer Awareness Month | whitehouse.gov
in fighting prostate cancer, we are still mindful that it remains the second leading cause of cancer deaths among men.  My Administration remains dedicated to finding better diagnostic and treatment options through the 21st Century Cures Act, as well as research collaborations between the Department of Health and Human Services, private industry, and the academic community.  In addition, the National Institutes of Health is investing in research that will improve upon current approaches to combatting prostate cancer.  Through these efforts and others, American men can experience a healthier future. This month, I encourage men to talk with their healthcare providers about their risk for prostate cancer.  I also call upon all Americans to do their part in raising awareness of this disease.  We pray for Americans currently fighting prostate cancer and recognize the progress yet to be made in finding its cure. 

San Diego Community News Group - Events set to highlight Prostate Awareness Month 
Texting“4Cure” to 20222 is the easiest thing you can to show your support for Prostate Awareness Month, also known as “Blue September.” 

What is “Blue September?”

September is Prostate Cancer Awareness Month, also referred to as “Blue September.”

First conceptualized in New Zealand in 2008, Blue September expanded to Australia in its second year. This year, thanks to some local efforts, the campaign has evolved into an international awareness and fundraising initiative.

San Diego radio personality Steve West of 91X helped launch the campaign here in San Diego with a 40-hour, non-stop resurrection marathon over Labor Day weekend, raising money for preventative research to help find a cure for this highly-curable cancer. West was diagnosed with prostate cancer in July 2004 and — because of early detection — was able to beat it. Actually, West’s discovery of his prostate cancer happened quite accidentally. He went to his doctor because he was having extreme migraines.

“Apparently, my head that is always up my ass knew there was a problem!” West joked.

While there, his doctor mentioned that West had never had a prostate-specific antigen (PSA) test — a primary tool to used to identify possible prostate cancer.

“Because of the test, I am here today,” West said
 

September Is National Prostate Cancer Awareness Month -

As the month of September brings prostate cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated prostate cancer information throughout the year.
Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer death in men, second only to lung cancer. According to American Cancer Society, there will be an estimated 192,280 new cases of prostate cancer and an estimated 27,360 deaths in the United States during 2009.[1] Staying informed with the latest news on prevention and screening is an important step in reducing your risk of developing prostate cancer. And, should a diagnosis occur, access to current, in-depth treatment information can help you find the best care.

Learning More About Prostate Cancer

  • Find great tips on recognizing early symptoms of prostate cancer and insight into management of the disease at http://www.cancerconsultants.com/cancer-tips/.
  • To find expanded information on the prevention, screening, and treatment of prostate cancer, and stay updated with the lasted news on the disease, visit the Prostate Cancer Information Center.
  • Sign up to receive Cancer Consultants’ free online prostate cancer newsletter, which provides disease-specific features, current news, tips, and nutrition and wellness information. Subscribe at http://www.cancerconsultants.com/about-cancerconsultants/subscription/.
  • Visit the Cancer Store on Cancerconsultants.com for books whose topics range from personal cancer memoirs to expert nutritional guides about fueling your body to prevent and fight cancer.

Let’s make it “Prostate Cancer Education Month”.  

If you’re already aware - we’d like to help you with your journey.
To accomplish that we are doing a series of webinars on the first 3 Wednesdays of September, called Webinar Wednesdays. (we will do the same in Oct, Nov, and Dec – stay tuned).
Jan Manarite
The first Webinar Wednesday is this Wed, Sept 6th
from 2:00 – 3:00 pm Eastern Time.

Led and moderated by Jan Manarite.

Intended Audience: Men who are Newly Diagnosed with prostate cancer, or their wives or partners.
Goal: To help you understand your medical records and Risk Category.  Every prostate cancer is different - do you understand yours?  It will help with your research, questions, and decisions.
Pre-Registration Required. For questions or to register, email Jan - JManarite@hotmail.com     
--------------------------------------------------------------------------------------------
The second Webinar Wednesday is Wed, Sept 13th
from 2:00 – 3:00 pm Eastern Time.

Intended Audience:  Men who are on Active Surveillance, or considering Active Surveillance.
Goal:  Have some meaningful discussion about other men's experiences - successes or failures.  How do they 'surveil' their prostate cancer?  What tips do they have for you.

Led and moderated by Mike Scott.  There will be several experienced AS patients on the call - learn from them.
Pre-Registration Required:  For questions or to register, email Jan - JManarite@hotmail.com

----------------------------------------------------------------------------
The third Webinar Wednesday is Wed, Sept 20th
from 2:00 – 3:30 pm Eastern Time.

Intended Audience:    
  • Ideally for patients (and their partners), who are planning to start ADT
    in the near future

    OR
  • Ideally for patients currently on ADT, and their partners, concerned about
    ADT side effects.
Goal:  Learn about solutions for side effects, and promote understanding between patients and partners as they experience the ADT journey together.

Presented by author and PC patient Richard Wassersug, PhD.  Moderated by Jan Manarite



. Purchase of book, Androgen Deprivation Therapy highly recommended.
Pre-Registration Required:  For questions or to register, email Jan - JManarite@hotmail.com

----------------------------------------------------------
Visit The "New" Prostate Cancer InfoLink Social Network at: http://prostatecancerinfolink.ning.com/?xg_source=msg_mes_network
To control which emails you receive on The "New" Prostate Cancer InfoLink Social Network, click here